> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Mylan 6-Item Form FDA-483 Posted
- URL: https://www.fdaweb.com/mylan-6-item-form-fda-483-posted/
- Published: 2025-01-03T12:00:00.000Z
- Updated: 2026-09-14T14:49:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158423

FDA has released a six-item Form [FDA-483](https://www.fda.gov/media/184861/download?ref=fdaweb.com) that led to a 12/19 [Warning Letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viatris-inc-690897-12192024?ref=fdaweb.com) to Mylan Laboratories citing its Pradesh, India manufacturing facility. A 6/14-6/26/2024 inspection found multiple violations, including significant GMP issues for finished drugs. Some specific violations were:

- failure to establish and follow adequate written responsibilities and procedures applicable to the quality control unit; and
- failure to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch had already been distributed.
- Equipment and utensils are not cleaned at appropriate intervals
- Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures

The agency's letter recommended that the company engage a qualified consultant to assist it in meeting GMP requirements. The letter also cited a need for data integrity remediation and a review of all quality assurance program audits and inspections within the last five years. Products from the Mylan Pradesh facility were placed on a 12/19 Import Alert.